期刊
JOURNAL OF MEDICAL VIROLOGY
卷 93, 期 4, 页码 1943-1949出版社
WILEY
DOI: 10.1002/jmv.26453
关键词
antibody; antiviral; COVID-19; glycan; safety; SARS-CoV-2; vaccine; virus
类别
Live unattenuated vaccines (LUVs) have been underestimated for decades due to safety concerns, but they have the potential to be safe and effective in controlling viral diseases, especially with the development of modern technologies like humanized monoclonal antibodies. Further research with animal experiments and clinical trials is needed to explore their efficacy in combating the COVID-19 pandemic caused by SARS-CoV-2.
Live unattenuated vaccines (LUVs) have been neglected for decades, due to widespread prejudice against their safety, even though they have successfully controlled yellow fever and adenovirus infection in humans as well as rinderpest and infectious bursal disease in animals. This review elucidated that LUVs could be highly safe with selective use of neutralizing antivirus antibodies, natural antiglycan antibodies, nonantibody antivirals, and ectopic inoculation. Also, LUVs could be of high efficacy, high development speed, and high production efficiency, with the development of humanized monoclonal antibodies and other modern technologies. They could circumvent antibody-dependent enhancement and maternal-derived antibody interference. With these important advantages, LUVs could be more powerful than other vaccines for controlling some viral diseases, and they warrant urgent investigation with animal experiments and clinical trials for defeating the COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据